
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp has strengthened its balance sheet through a new five-year interest-only credit facility, securing up to $60 million in committed capital and extending debt maturity to 2031. The company's Q3 2025 financial results showed a revenue increase of 5% year-over-year to $21.5 million, with international revenue growth outpacing the U.S. segment, alongside a maintained gross margin of 75%. Additionally, Pulmonx reported a full-year revenue growth to $90.5 million from $83.8 million in 2024, highlighting improved operational efficiency and a strategic focus on increasing the eligible patient pool through innovative treatment approaches.
Bears say
Pulmonx Corp reported modest annual revenue growth of 8%, totaling $90.5 million for the full year 2025, yet experienced a decline in fourth-quarter revenue to $22.6 million, primarily due to weakened performance in the U.S. market. The company's cash, cash equivalents, and marketable securities decreased by approximately $32 million year-over-year, totaling $69.8 million at year-end 2025, with expectations of an additional $23 million decline in cash throughout 2026 without further credit facility drawdowns. Furthermore, with operating expenses reaching $120.8 million and a net loss of $54.0 million, Pulmonx's financial stability remains a concern, indicating potential challenges in achieving sustainable growth.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares